We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
ImClone Systems, an Eli Lilly subsidiary, and Bristol-Myers Squibb (BMS) received an FDA complete response letter for an sBLA seeking an Erbitux indication for the first-line treatment of squamous cell carcinoma of the head and neck.